FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutical application of selective negative allosteric modulators GABA A α5 for treatment, prevention and/or retardation of development of central nervous system condition, related to excessive GABA-ergic inhibition in brain. Claimed are: application of negative allosteric modulator GABA A α5, (1,1-dioxo-1,6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone or its pharmaceutically acceptable salt for treatment, prevention and/or retardation of development of said CNS conditions, selected from cognitive disorders in case of Down's syndrome, autism, type I neurofibromatosis or after stroke (versions) and pharmaceutical composition for said purpose.
EFFECT: compound reverses deficiency of long-time neuron potentiation, restores neuron proliferation and density of granular cells in hippocampus, and recovers impaired spatial learning.
13 cl, 23 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID FORMS OF (1,1-DIOXO-4-THIOMORPHOLINYL) - [6 - [[3- (4-FLUOROPHENYL) -5-METHYL-4-ISOXAZOLYL] METHOXY] -3-PYRIDINYL] METHANONE | 2012 |
|
RU2618524C2 |
| TRIAZOLE DERIVATIVES AS GABA RECEPTOR LIGANDS | 2011 |
|
RU2582337C2 |
| TRIAZOLE DERIVATIVES AND APPLICATION THEREOF IN NEUROLOGICAL DISEASES | 2011 |
|
RU2581504C2 |
| ARYL-IZOXAZOLE-4-YL-IMIDAZO[1,5-a]PYRIDINE DERIVATIVES | 2006 |
|
RU2420527C2 |
| NEW ETERIAL DERIVATIVES OF ISOXAZOLE AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A ALFA 5 RECEPTOR | 2017 |
|
RU2772862C2 |
| NOVEL TRIAZOLE COMPOUNDS | 2011 |
|
RU2588137C2 |
| IMIDEAZOQUINOXALINES | 1992 |
|
RU2092487C1 |
| DIAZABICYCLIC ARYL DERIVATIVES AS LIGANDS OF NICOTINIC ACETYLCHOLINE RECEPTORS | 2005 |
|
RU2367665C2 |
| TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GAMMA-AMINOBUTYRIC ACID RECEPTORS | 2005 |
|
RU2393161C2 |
| IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS (VERSIONS), METHOD FOR PREPARING IMIDAZO[1,2-b]PYRIDAZINE COMPOUNDS (VERSIONS), PHARMACEUTICAL COMPOSITION AND DRUG PREPARATION FOR TREATING AND/OR PREVENTING DISEASES RELATED TO GAB RECEPTOR INHIBITION | 2007 |
|
RU2486188C9 |
